Skip to main content
Figure 8 | BMC Cancer

Figure 8

From: The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts

Figure 8

Evaluation of RANKL/OPG ratio by ELISA in conditioned medium of MSC exposed to dasatinib. Cells were treated or not with 10-8 and 10-7 M dasatinib in the absence of DAG for 3 and 7 days. 24-hours conditioned medium were collected at the end of the treatment time. RANKL and OPG protein levels were measured by ELISA in conditioned medium (1 ml/105 cells) and normalized to total protein content. Data are presented as RANKL/OPG ratio (mean ± SEM from 4 independent experiments). *** p < 0.001 versus the corresponding control.

Back to article page